XSHE
300760
Market cap33bUSD
Oct 30, Last price
181.75CNY
1D
1.54%
1Q
14.39%
IPO
135.12%
Name
Shenzhen Mindray Bio-Medical Electronics Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating on a global scale, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. specializes in providing a comprehensive range of medical devices and innovative healthcare solutions. Its extensive portfolio encompasses several key segments. Within patient monitoring and life support, the company manufactures crucial equipment such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, and endoscopes, along with associated accessories. This segment also delivers integrated solutions for emergency care, peri-operative management, critical care, and medical IT systems. For in-vitro diagnostics, Mindray offers sophisticated products including hematology and chemistry analyzers and their reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry instruments, and microplate readers and washers. These are further supported by solutions tailored for coagulation, urinalysis, and microbiology. The company additionally produces advanced medical imaging systems, covering both ultrasound and radiology products, and supplies a dedicated line of veterinary products. Founded in 1991, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. maintains its primary operational base in Shenzhen, People's Republic of China.
Key people
Finance Director · since 2019
Jian Cen
Deputy General Manager · since 2024
Yanmei Guo
Executive Deputy General Manager, Director · since 2021
Xujin He
Deputy General Manager · since 2024
Chaoyang Li
Deputy General Manager · since 2024
Zaiwen Li
Senior Deputy General Manager
Senior Deputy General Manager · since 2024
Deputy General Manager · since 2017
Huawen Yan
Deputy General Manager · since 2024
Wenmei Li
Secretary of the Board · since 2017
Minghe Cheng
Vice Chairman of the Board · since 2020
Xiting Li
Chairman of the Board · since 2017
Hao Wu
General Manager, Director · since 2020
Hang Xu
Director · since 1999
Shengping Gao
Independent Director · since 2023
Minkang Gu
Independent Director · since 2025
Shanrong Hu
Independent Director · since 2023
Yu Kong
Independent Director · since 2023
Huming Liang
Independent Director · since 2021
Jing Xu
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||